Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the appointment of
Mark R. Willig as new Chief Commercial Officer.
Mark Willig joins Exiqon from Thermo Fisher Scientific, Inc. where he held a
position as Vice President of Global Sales since 2007 serving customers within
the pharmaceutical and biotech industry, hospitals, clinical laboratories,
research institutions and government agencies.
Prior to Thermo Fisher Scientific, Inc., Mark has served in various senior
management positions at Prognostix, Inc., Specialty Labs, Inc., Myriad
Genetics, Inc. and Orca Medical Systems, Inc. Mark brings more than 20 years of
sales and marketing experience.
Mark Willig will be responsible for managing sales & marketing of all products
and services in both of Exiqon's two financial segments: Exiqon Diagnostics
and Exiqon Life Sciences. Mark Willig replaces Erik Holmlin.
Lars Kongsbak, President and CEO says: ”Mark brings to Exiqon important sales
management skills and experience with the markets in which we operate. We are
excited to have him join our team and support our continued efforts to
establish Exiqon as a market leader for miRNA diagnostics and miRNA research
based on our proprietary LNA™ detection technology”.
Additional information:
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
Read the full announcement in the attached PDF or at
www.exiqon.com/investor/portal.
